represented by the Secretary;The United States of America;The United States of America, represented by the Secretary, Department of Health and Human Services;The Board Of Trustees Of The UniversityOf Illinois; Department of Health and Human Services
发明人:
Erickson, John W.,Gulnik, Sergei V.,Mitsuya, Hiroaki,Ghosh, Arun K.
申请号：
ES10179052
公开号：
ES2604662T3
申请日:
1999.06.23
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
An effective amount of resistance inhibitor of a compound of the formula: ** Formula ** in which: (i) A is ** Formula ** R3 is phenyl, R5 is isobutyl, and Ar is phenyl substituted with an m- group hydroxyl, an m- or p-hydroxymethyl group, or a p-aminomethyl group； or (ii) A is ** Formula ** R3 is R5 is isobutyl, and Ar is p-methoxyphenyl； (iii) A is ** Formula ** R3 is phenyl, R5 is ** Formula ** and Ar is m-methoxyphenyl； or (iv) A is ** Formula ** R3 is phenyl, R5 is isobutyl, and Ar is p-aminophenyl for use in the treatment of an HIV-infected mammal that is infected with a mutant HIV, in combination with a antiviral agent selected from the group consisting of ritonavir, indinavir and saquinavir in a pharmaceutically acceptable vehicle, in which said treatment prevents the emergence of drug resistance due to additional mutations.Una cantidad eficaz inhibidora de la resistencia de un compuesto de fórmula: **Fórmula** en el que: (i) A es **Fórmula** R3 es fenilo, R5 es isobutilo, y Ar es fenilo sustituido con un grupo m-hidroxilo, un grupo m- o p-hidroximetilo, o un grupo p-aminometilo； o (ii) A es**Fórmula** R3 es R5 es isobutilo, y Ar es p-metoxifenilo； (iii) A es **Fórmula** R3 es fenilo, R5 es **Fórmula** y Ar es m-metoxifenilo； o (iv) A es **Fórmula** R3 es fenilo, R5 es isobutilo, y Ar es p-aminofenilo para su uso en el tratamiento de un mamífero infectado por el VIH que está infectado con un VIH mutante, en combinación con un agente antiviral seleccionado del grupo que consiste en ritonavir, indinavir y saquinavir en un vehículo farmacéuticamente aceptable, en el que dicho tratamiento previene la aparición de resistencia a los medicamentos debido a mutaciones adicionales.
